Company intelligence / Profile preview
Bright Cell, Inc.
Irvine, California, United Statesbrightcellgroup.com ↗
- Ownership
- Public · BHG
- Development stage
- Phase 2
01
Overview
Bright Cell, Inc. has two drug candidates in Phase 1 clinical trials: YB-1113 for Premature Ovarian Insufficiency and human umbilical cord tissue derived mesenchymal stem cells for nasolabial fold wrinkles. A Phase 1 study for YB-1113 is scheduled to start on January 9, 2025, to evaluate safety and tolerability via intravenous infusion.[2][6]
- Therapeutic areas
- Women's HealthDermatology
- Modalities
- Mesenchymal stem cell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Bright Cell, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bright Cell, Inc..